I documenti di: quotidianosanità.it Quotidiano online di informazione sanitaria Dossier Documentazione legislativa Studi e ricerche Interventi e relazioni 04 April 2014 EMA/ 145085/ 2014 I nspect ions and Hum an Medicines Pharm acovigilance 2013 Annual Report on EudraVigilance for t he European Parliam ent , t he Council and t he Com m ission Report ing period: 1 January t o 31 Decem ber 2013 7 West ferry Cir cus Canary Wharf London E14 4HB Unit ed Kingdom Te le phone + 44 ( 0) 20 7418 8400 Fa csim ile + 44 ( 0) 20 7418 8668 E- m a il info@em a.europa.eu W e bsit e ww w.em a.europa.eu An agency of t he Eur opean Union © European Medicines Agency, 2014. Reproduct ion is aut horised prov ided t he sour ce is acknow ledged. Ta ble of Con t ent s 1 . I n t r odu ct ion ............................................................................................ 3 2 . D e ve lopm e n t of n e w fu n ct ion a lit ie s ........................................................ 3 3 . D a t a colle ct ion a n d da t a qu a lit y .............................................................. 4 4 . D a t a a n a lysis ........................................................................................... 5 5 . Tr a n spa r e n cy, com m u n ica t ion a n d t r a in in g ............................................. 6 6 . Con clusion ............................................................................................... 7 An n ex I - Su m m a r y of Eu dr a Vigila n ce r e la t e d a ct ivit ie s .............................. 8 An n ex I I – Eu dr a Vigila n ce da t a - pr oce ssin g n et w or k a n d nu m be r of suspe ct e d a dver se r e a ct ion r e por t s pr oce sse d by t h e Eu dr a Vigila n ce da t a ba se ...................................................................................................... 9 EudraVigilance dat a- processing net wor k ( EudraVigilance Gat eway) ................................... 9 EudraVigilance dat abase .............................................................................................. 9 E- r eport ing st at us for MAHs and sponsor s of clinical t rials .............................................. 12 E- r eport ing st at us for NCAs ........................................................................................ 13 EudraVigilance dat abase and support of signal m anagem ent process ............................... 14 An n ex I I I - Tot a l n u m be r of m e dicin a l pr odu ct su bm ission s by M AH s ....... 1 5 An n ex I V - Eu dr a Vigila n ce da t a qu a lit y a ct ivit ie s ...................................... 1 6 An n ex V – Sign a l de t e ct ion ........................................................................ 1 7 Ov erview of signals validat ed by t he Agency priorit ised and assessed by t he PRAC............ 18 An n ex VI - Sign a l m a n a ge m e n t in t h e EU .................................................. 2 2 An n ex VI I - Re qu est s for infor m a t ion a n d docu m en t s ............................... 2 3 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 2/ 28 1 . I n t rodu ct ion The European Medicines Agency ( EMA) works wit hin t he European Regulat ory Net work t o support t he m onit oring of t he safet y of m edicines. The EMA's m ain responsibilit ies in t his area include t he coordinat ion of t he European pharm acovigilance syst em , t he provision of inform at ion on t he safe and effect ive use of m edicines and operat ing and m aint aining EudraVigilance ( EV) and t he EudraVigilance Dat a Analysis Syst em ( EVDAS) . Bot h EMA and m edicines regulat ory aut horit ies in Mem ber St at es are required by legislat ion t o cont inuously m onit or t he adverse react ion dat a report ed t o EudraVigilance t o det erm ine whet her t here are new risks or know n risk s which have changed and whet her t hose risks have an im pact on t he overall benefit - risk balance of a m edicine. I n t he cont ext of t he im plem ent at ion of t he new phar m acovigilance legislat ion 1 , m aj or em phasis is being been put on furt her st rengt hening t he role of EudraVigilance as regards sim plifying adverse react ion report ing, collect ing adverse react ions report ed by pat ient s and consum ers ( as well as t hose from healt hcare professionals) , det ect ing new risks, m onit oring known or pot ent ial risks, risk assessm ent by t he Pharm acovigilance Risk Assessm ent Com m it t ee ( PRAC) and increasing t ransparency by providing st akeholders wit h adequat e access t o adverse react ion dat a and analysis ( via EVDAS and elect ronic React ion Monit oring Report s, eRMRs) . I n com pliance wit h t he EU pharm acovigilance legislat ion 2 , t he EMA has prepared t his annual report for t he European Parliam ent , t he Council and t he Com m ission t o provide a sum m ary of t he EudraVigilance relat ed act ivit ies t hat t he EMA undert ook in 2013 wit hin t he EU regulat ory net work and wit h st akeholders. 2 . D e velopm en t of ne w fun ct ion a lit ie s The revised pharm aceut ical legislat ion foresees furt her im provem ent s in t he funct ionalit y of EV. I n accordance wit h Art icle 24 of Regulat ion ( EC) 726/ 2004 3 , t he Agency, in collaborat ion wit h t he Mem ber St at es and t he Com m ission, shall draw up t he funct ional specificat ions for t he EudraVigilance dat abase ( hereaft er referred t o as “ EudraVigilance funct ionalit ies t o be audit ed” ) t oget her wit h a t im efram e for t heir im plem ent at ion. The EudraVigilance funct ionalit ies t o be audit ed focus on t he key deliverables which will benefit Mem ber St at es, pharm aceut ical indust ry and furt her st rengt hen t he prot ect ion of public healt h. More specifically, t hey will deliver: • Sim plificat ion of adverse r eact ion report ing • High- qualit y and int egrit y of pharm acovigilance inform at ion held in EudraVigilance • Adapt at ion t o t echnical and scient ific progress by im plem ent at ion of t he I SO st andards for individual case safet y report s and ident ifying m edicines ( subj ect t o I SO t im elines) • Full im plem ent at ion of t he EudraVigilance Access Policy including access by m ar ket ing aut horisat ion holders t o t he ext ent necessary t o fulfil t heir pharm acovigilance obligat ions • St rengt hening of signal det ect ion com plem ent ed by st at ist ical analysis 1 Regulat ion ( EC) No. 726/ 2004, Direct ive 2001/ 83/ EC Regulat ion ( EC) No. 726/ 2004 Art icle 24( 2) , paragraph 2 3 Regulat ion ( EC) No. 726/ 2004 of t he European Parliam ent and of t he Council of 31 March 2004 laying dow n Com m unit y procedures for t he aut horisat ion and supervision of m edicinal product s for hum an and vet erinary use and est ablishing a European Medicines Agency 2 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 3/ 28 • Elect ronic report ing of EU cases t o t he World Healt h Organisat ion Uppsala Monit oring Cent re. The EudraVigilance funct ionalit ies t o be audit ed have followed t he consult at ion process of t he EMA/ Mem ber St at es governance st ruct ure for t he im plem ent at ion of t he pharm acovigilance legislat ion including t he endorsem ent by t he EU Telem at ics Managem ent Board, t he Pharm acovigilance Risk Assessm ent Com m it t ee and t he EMA Managem ent Board. Following endorsem ent by t he EMA Managem ent Board in Decem ber 2013, t he EudraVigilance funct ionalit ies t o be audit ed will provide a basis for EMA t o develop a det ailed proj ect plan including t he t im elines for im plem ent at ion and t he plan for t he conduct of an independent audit . Moreover, on t he basis of t he endorsed funct ionalit ies, det ailed business requirem ent s will be developed by t he EMA in consult at ion wit h Mem ber St at es, which aim t o furt her analyse t he end- users’ needs. Following com plet ion of t he syst em design and developm ent , user t est ing wit h Mem ber St at es will be perform ed. The delivery of t he agreed funct ionalit ies will be accom panied by end- users t raining. PRAC will be regularly updat ed on t he proj ect m ilest ones and progress m ade and a PRAC recom m endat ion, as required by legislat ion, will be sought for t he audit t hat t he funct ionalit ies have been delivered. Based on an independent audit report t hat t akes int o account t he recom m endat ions of t he PRAC, t he EMA Managem ent Board w ill confirm and announce w hen full funct ionalit y of t he EudraVigilance dat abase has been achieved and t he syst em m eet s t he defined funct ional specificat ions. This will bring t he new requirem ent s of t he Regulat ion 4 int o force. 3 . D a t a colle ct ion a n d da t a qu a lit y One of t he deliverables 5 of t he pharm acovigilance legislat ion focuses on t he elect ronic subm ission of a core dat a set on all m edicinal product s aut horised in t he EU by m ar ket ing aut horisat ion holders ( MAHs) . Following publicat ion of a Legal Not ice, 6 and an elect ronic subm ission form at , t he EMA collect ed t hese dat a as part of t he eXt ended EudraVigilance Medicinal Product Dict ionary ( xEVMPD) wit h t he prim ary obj ect ive of facilit at ing dat a analysis and signal det ect ion t o support bet t er safet y m onit oring for pat ient s. The t ot al num ber of m edicinal product subm issions by MAHs during 2013 is present ed in Annex I I I . From July 2012, t he phar m acovigilance legislat ion also int roduced direct report ing of adverse react ions by pat ient s and consum ers in all Mem ber St at es and enhanced adverse react ion report ing in t he cont ext of post - aut horisat ion st udies, m edicat ion errors, off- label use and occupat ional exposure. The num ber of report s relat ed t o suspect ed serious adverse react ions collect ed and m anaged in EudraVigilance in 2013 is provided in Annex I I . 2013 shows an increase in t he level of report ing com pared t o previous year s, and, in part icular, a significant increase in t he level of direct pat ient report ing com pared t o previous years. EudraVigilance cont inues t o support t he report ing of suspect ed unexpect ed serious adverse react ions ( SUSARs) in accordance wit h EU clinical t rial legislat ion 7 ( see Annex I I ) . 4 Art icle 24 of Regulat ion ( EC) No. 726/ 2004 as am ended by Regulat ion ( EU) No. 1235/ 2010 Regulat ion ( EC) No. 726/ 2004, Art icle 57( 2) , second subparagraph 6 Legal not ice on t he im plem ent at ion of Art icle 57( 2) , second subparagraph of Regulat ion ( EC) No. 726/ 2004 ( Doc. Ref. 5 March 2012 EMA/ 505633/ 2011) 5 7 Direct ive 2001/ 20/ EC of t he European Parliam ent and of the Council of 4 April 2001 on t he approxim at ion of t he laws, regulat ions and adm inist rat ive provisions of t he Mem ber St at es relat ing t o t he im plem ent at ion of good clinical pract ice in t he conduct of clinical t rials on m edicinal product s for hum an use 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 4/ 28 Qualit y assurance is key t o support pharm acovigilance. I n accordance wit h t he pharm acovigilance legislat ion, t he EMA is operat ing procedures t hat ensure t he qualit y and int egrit y of t he inform at ion collect ed in EudraVigilance. This refers specifically t o t he adequat e ident ificat ion of m edicinal product s associat ed wit h report ed adverse react ions, rem oval of duplicat e report s, t im ely subm issions of serious adverse react ions, adherence t o coding pract ices and st andards as well as adequat e case docum ent at ion, which for m t he basis for successful dat a analysis and decision m aking t o prot ect public healt h. The EMA’s effort s in im proving dat a qualit y include t raining provision, det ect ing and m erging duplicat e report s, perform ing I CSR dat a qualit y reviews, providing feedback t o individual report ing organisat ions and conduct ing recoding of adverse react ion report s ut ilising t he m edicinal product dat a of t he XEVMPD. These are sum m arised in Annex I V. 4 . D a t a a n alysis The legislat ion also int roduced clearly defined responsibilit ies for signal det ect ion and m anagem ent in t he EU for t he Agency and t he NCAs. A safet y signal r efers t o inform at ion on one or m ore newly observed adverse react ions pot ent ially caused by a m edicine and t hat warrant furt her invest igat ion. I f a safet y concern is confirm ed or considered likely t o be associat ed wit h a m edicinal product , regulat ory act ion m ay be necessary and usually t akes t he form of an updat e of t he sum m ary of product charact erist ics ( Sm PC) and t he pat ient leaflet . Som et im es a signal ident ifies safet y concerns requiring act ion beyond Sm PC changes, e.g. rest rict ion of use t o populat ions in which t he benefit - risk balance rem ains posit ive or t he need for gat hering furt her dat a from addit ional sources ( e.g. observat ional st udies, regist ries) t o bet t er assess t he risk. EudraVigilance is a key t ool in operat ing t he new signal m anagem ent processes in t he EU. EMA st aff lead on t he det ect ion and init ial validat ion of safet y signals for cent rally aut horised m edicinal product s ( CAPs) and t he NCAs are leading for non- CAPs. Am ong safet y signals reviewed by t he EMA in 2013, m ore t han 90% originat ed from EudraVigilance. Det ails of signal det ect ion act ivit ies are present ed in Annex V and progress in t erm s of signal m anagem ent in t he EU is described in Annex VI . Addit ionally, EMA prepares dat a out put report s ( elect ronic react ion m onit oring report s, e- RMRs) t o support m onit oring of dat a by NCAs in cont ext of t he work- sharing of m onit oring EV dat a. Over 19,000 of t hese e- RMRs were generat ed and dist ribut ed t o NCAs and EMA st aff in 2013. I n 2013, t he PRAC priorit ised and assessed 100 signals, t ot alling 130 signal discussions. This includes 43 signals det ect ed and validat ed by t he EMA and 57 det ect ed and validat ed by Mem ber St at es. Am ong t he signals raised by t he EMA, t he evaluat ion of 21 signals result ed in changes of t he product inform at ion ( including t he dist ribut ion of a Direct Healt hcare Professional Com m unicat ion in four cases in order t o highlight im port ant new inform at ion t o prescribers) . The evaluat ion of 14 signals is current ly at t he st age of an assessm ent of dat a provided by MAHs and t he evaluat ion of 7 signals was concluded following t he assessm ent of available dat a wit h no furt her regulat ory act ion. For one signal, a form al review of benefit - risk in t he scope of a refer ral under art icle 31 of Direct ive 2001/ 83/ EC was init iat ed. Overall, t he evaluat ion of signals by t he PRAC has led t o t im ely conclusions of safet y reviews and appropriat e act ions for t he prot ect ion of public healt h. I n addit ion t o t he use of EudraVigilance for signal m anagem ent , furt her em phasis has been put on t he support of pharm acovigilance referral procedures ( incl. urgent union procedures) by providing and analysing safet y dat a for t he m edicinal product s concerned. I n 2013, t hese act ivit ies focused on m edicinal product s cont aining t he act ive subst ances alm it rine, codeine, com bined cont racept ives, cyprot erone/ et hinylest radiol, diacerin, dihydrocodeine, dom peridone, est radiol ( t opical use) , flupirt ine, 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 5/ 28 nicot inic acid and derivat ives, st ront ium ranelat e, solut ions for infusion cont aining hydroxyet hyl st arch, t et razepam , valproat e and relat ed subst ances, zolpidem . To support t he assessm ent of PSURs by Mem ber St at es, EMA is also providing addit ional dat a analysis report s from EudraVigilance and providing t raining t o assessors. 5 . Tr a n spa r en cy, com m u nica t ion an d t r a in ing A key obj ect ive of t he new legislat ion is t o enhance t ransparency and opt im ise com m unicat ion in pharm acovigilance. Following t he adopt ion of t he EudraVigilance Access Policy in 2011, t he EMA launched in 2012 t he first phase of t he online access t o suspect ed adverse react ion report s 8 in all official languages of t he EU on a new public websit e: ww w.adrreport s.eu. The launch highlight s t he im port ance of adverse react ion report ing and EudraVigilance in safeguarding public healt h. The inform at ion current ly published relat es t o over 700 m edicines and act ive subst ances aut horised t hrough t he cent ralised procedure. I t is planned t o ext end t his websit e t o subst ances in nat ionally aut horised m edicines subj ect t o worksharing for signal m anagem ent in 2014. The websit e, available in all EU languages, was m aint ained t hroughout 2013 wit h 100% availabilit y. Signals assessed by t he PRAC are publicly available in t he cont ext of t he publicat ion of t he PRAC m eet ing agendas and m inut es 9 . I n Sept em ber 2013, t he Agency st art ed publishing t he adopt ed PRAC recom m endat ions 10 on signals, in order t o facilit at e t heir im plem ent at ion by t he MAHs ( e.g. changes t o t he product inform at ion) and t o increase t ransparency. The Agency published t he list of m edicinal product s subj ect t o addit ional m onit oring 11 in April 2013 and has m aint ained t he list prospect ively via m ont hly updat es. Medicines under addit ional m onit oring have a black invert ed t riangle displayed in t heir package leaflet and sum m ary of product charact erist ics, urging healt hcare professionals and pat ient s t o report any suspect ed adverse react ions via nat ional report ing syst em s. EMA also responds t o request s for EudraVigilance dat a in line wit h t he EudraVigilance Access Policy and EU legislat ion on access t o docum ent s 12 , and in com pliance wit h EU personal dat a prot ect ion 13 . Det ails on request s handled in 2013 are provided in Annex VI I . I n 2013 t he EMA organised four I nform at ion Days for ext ernal st akeholders from m edicines regulat ory aut horit ies and pharm aceut ical indust ry in relat ion t o EudraVigilance and t he new int ernat ional st andards in pharm acovigilance. Finally, t went y nine EudraVigilance and seven xEVMPD hands- on t raining courses were delivered t o st akeholders in 2013 wit h 228 users following xEVMPD e- learning t raining. Addit ionally, EVDAS ( EudraVigilance Dat awarehouse Analysis Syst em ) t raining was held at t he Agency on t hree occasions, t raining 44 expert s from 10 different NCAs. 8 ht t p: / / www .adrreport s.eu/ EN/ index.ht m l ht t p: / / www .em a.europa.eu/ em a/ index.j sp?curl= pages/ about _us/ docum ent _list ing/ docum ent _list ing_000353.j sp&m id= WC 0b01ac05805a21cf 10 ht t p: / / www .em a.europa.eu/ em a/ index.j sp?curl= pages/ regulat ion/ docum ent _list ing/ docum ent _list ing_000375.j sp&m id= WC0b01ac0580727d1c 11 ht t p: / / www .em a.europa.eu/ em a/ index.j sp?curl= pages/ regulat ion/ docum ent _list ing/ docum ent _list ing_000366.j sp&m id= WC0b01ac058067c852 12 Regulat ion ( EC) No. 1049/ 2001 of t he European Parliam ent and of t he Council of 30 May 2001 regarding public access t o European Parliam ent , Council and Com m ission docum ent s 13 Regulat ion ( EC) No. 45/ 2001 of t he European Parliam ent and of t he Council of 18 Decem ber 2000 on t he prot ect ion of individuals wit h regard t o t he processing of personal dat a by t he Com m unit y inst it ut ions and bodies and on t he free m ovem ent of such dat a 9 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 6/ 28 6 . Con clusion EudraVigilance cont inues t o be t he cent ral pillar t o support pharm acovigilance act ivit ies and t herefore cont ribut es t o t he prot ect ion of public healt h in t he EU. The ever increasing num ber of report s received in EudraVigilance is used for safet y m onit oring of m edicines by t he EMA and t he Mem ber St at es, decision m aking in signals, PSUR and referral procedures by t he Agency’s scient ific com m it t ees and is support ed by t ools for t ransparency for t he public, healt hcare providers, academ ia and MAHs. I n 2013 t ransparency was st rengt hened by t he publicat ion of adopt ed PRAC recom m endat ions for signals and by est ablishing t he List of m edicinal product s subj ect t o addit ional m onit oring. Furt her work was carried out in 2013 t o im prove t he dat a qualit y in EudraVigilance and a furt her increase was not ed in t he num ber of m edicinal product subm issions by t he MAHs, est ablishing t he m ost com plet e resource of aut horised m edicinal product s in t he EU. Following t he Managem ent Board endorsem ent of t he funct ional specificat ions for t he EudraVigilance dat abase ( “ EudraVigilance funct ionalit ies t o be audit ed” ) , t he Agency will cont inue t o work wit h t he Mem ber St at es in 2014 t o furt her define and develop enhanced funct ionalit ies for t he benefit of t he st akeholders and st ronger prot ect ion of public healt h. 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 7/ 28 An ne x I - Su m m a ry of Eu dr a Vigilan ce r ela t e d a ct ivit ie s I m ple m e nt a t ion a ct ivit ie s St a t u s Operat ion and m aint enance of EudraVigilance by EMA in collaborat ion Cont inued during 2013 wit h Mem ber St at es [ Legal basis: Regulat ion ( EC) 726/ 2004, Art icle 24] Dat a qualit y review and duplicat e m anagem ent of adverse react ion Cont inued during 2013 report s in EudraVigilance [ Legal basis: Regulat ion ( EC) 726/ 2004, Art icle 24( 3) ] Collect ion of core dat a set for all m edicinal product s aut horised in t he Cont inued during 2013 EU in EudraVigilance [ Legal basis: Regulat ion ( EC) 726/ 2004 Art icle 57( 2) , second subparagraph] Operat ion of t he signal m anagem ent processes based on Cont inued during 2013 EudraVigilance dat a, including t he m ont hly provision of e- RMRs t o lead Mem ber St at e for non- CAPs [ Legal basis: • • Regulat ion ( EC) 726/ 2004, Art icle 28( a) Direct ive 2001/ 83/ EC, Art icle 107( h) Com m ission I m plem ent ing Regulat ion ( EU) 520/ 212, Art icle 21] Access t o adverse react ion dat a held in EudraVigilance for CAPs Cont inued during 2013 ht t p: / / www.adrreport s.eu/ [ Legal basis: Regulat ion ( EC) 726/ 2004, Art icle 24] 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 8/ 28 An ne x I I – Eudra Vigilan ce da t a - pr ocessin g n e t w or k a nd num be r of su spe ct e d a dve rse re a ct ion re por t s pr ocesse d by t h e Eudr a Vigilan ce da t a ba se Eu dr a Vigila n ce da t a - pr oce ssin g n et w or k ( Eu dr a Vigila n ce Ga t e w a y) The EudraVigilance dat a- processing net work as referred t o in Art icle 24 of Regulat ion ( EC) No. 726/ 2004 facilit at es t he elect ronic exchange of adverse react ion report s bet ween t he EMA, m edicines regulat ory aut horit ies and MAHs for all m edicines aut horised in t he European Econom ic Area ( EEA) . This net work, know n as t he EudraVigilance gat eway, has been in cont inuous operat ion since Decem ber 2001. During 2013, a t ot al of 15,747,644 t ransact ions were successfully perform ed by t he EudraVigilance gat eway. Figure 1 present s t he t ot al num ber of t ransact ions perform ed per m ont h during 2013. 1,600,000 1,400,000 1,200,000 1,000,000 800,000 600,000 400,000 200,000 0 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Figur e 1 . Tot al num ber of t ransact ions perform ed per m ont h at t he level of t he EudraVigilance Gat eway from 1 January 2013 – 31 Decem ber 2013 Eu dr a Vigila n ce da t a ba se For m edicinal product s aut horised in t he EEA, adverse react ions report s are collect ed from bot h wit hin and out side t he EEA. The num bers present ed in figure 2 refer t o t he adverse react ion report s 14 received in t he post aut horisat ion m odule. During 2013, an average of 88,474 expedit ed adverse react ion report s were received and processed per m ont h and subsequent ly m ade available for signal det ect ion and dat a analysis by EMA and m edicines regulat ory aut horit ies in t he Mem ber St at es. 14 I n t he 2012 report , only "expedit ed" adverse react ion report s were present ed. Wit h t he new legislat ion, which has been in force t hroughout 2013, alm ost all report s t ransm it t ed t o EudraVigilance are expedit ed, so t hese figures are for all I CSRs/ cases t ransm it t ed t o EV. 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 9/ 28 120,000 100,000 80,000 60,000 40,000 20,000 0 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Figur e 2 . Num ber of adverse react ion report s processed per m ont h in t he EudraVigilance dat abase post - aut horisat ion m odule in 2013 Figure 3 present s t he t ot al num ber of adverse react ion report s 15 received in t he post - aut horisat ion m odule grouped by EEA and non- EEA for 2013. Each individual case in EudraVigilance refers generally t o a single pat ient ; an individual case is com posed of at least one report , called t he init ial report , which m ight be com plem ent ed by follow- up report s wit h updat ed addit ional inform at ion on t he case. 1,200,000 1,000,000 800,000 750,916 600,000 485,471 400,000 200,000 370,185 256,900 0 I ndividual cases Adverse react ion report s EEA Non- EEA Figur e 3 . Num ber of individual cases/ adverse react ion report s processed bet ween Januar y and Decem ber 2013 in t he Eudravigilance dat abase post - aut horisat ion m odule 15 I n t he 2012 report , only "expedit ed" adverse react ion report s and individual cases were present ed. Wit h t he new legislat ion, which has been in force t hroughout 2013, alm ost all report s t ransm it t ed t o Eudravigilance are expedit ed, so t hese figures are for all I CSRs/ cases t ransm it t ed t o EV. 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 10/ 28 One very significant effect of t he new pharm acovigilance legislat ion was t o int roduce an obligat ion for MAHs & NCAs t o inform t he Agency about adverse react ions report s received direct ly from pat ient s. Wit hin t he EEA, t his has led t o t he num ber of such report s received in EudraVigilance each year increasing significant ly ( and at a higher rat e t han t he increase in t he t ot al num ber of cases) since t he ent ry int o force of t he new legislat ion ( 13,936 individual cases originat ing from consum ers were t ransm it t ed t o EV in 2011, and 30,614 were t ransm it t ed t o EV in 2013) . Figure 4 shows t he increase in t he num ber of EEA cases year- on- year and t he proport ionat ely great er increase in t he num ber of direct pat ient report s, from 2011 ( t he last whole year before t he ent ry int o force of t he new pharm acovigilance legislat ion) t o 2013. The num bers have been norm alised t o 2011 values ( t aking 2011 as 100) t o show t he com parat ive rat es of increase in direct pat ient report s versus all report s. Table 1, im m ediat ely below Figure 4, gives bot h t he norm alised and t he t rue values. Figur e 4 . The increase in t he rat e of direct pat ient report s com pared t o t he increase in t he rat e of all report s from t he EEA following t he ent ry int o force of t he new PV legislat ion D ir e ct pa t ie nt ca se s Tot a l ca se s 250,000 35,000 30,000 200,000 25,000 150,000 20,000 15,000 100,000 10,000 50,000 5,000 0 0 2011 2012 2011 2013 2012 2013 Num ber of direct pat ient cases & t ot al cases t ransm it t ed t o EV each year from 2011 t o 2013 Ta ble 1 . The rat e of direct pat ient and t ot al EEA case report ing 2011- 2013 Year Re por t e r 2011 2012 2013 N um be r of % of 2 0 1 1 N um be r of % of 2 0 1 1 N um be r of % of 2 0 1 1 t ype ca se s rates ca se s rates ca se s rates Pa t ie nt 13,936 100 20,115 144 30,614 220 163,275 100 186,136 114 234,546 144 Tot a l 16 True & norm alised values for EEA cases report ed t o EVPM year - on- year t aking 2011 as t he baseline for t he norm alised values 16 These num bers do not t ake int o account t he de- duplicat ion w ork because t hey are concerned wit h t he increase in t he rat e of report ing by prim ary sources and not t he rat e of t ransm ission of I CSRs t o EV by MAHs or NCAs, and t herefore t hey are not direct ly com parable t o t he num bers present ed in figures 2 and 3. 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 11/ 28 By 31 Decem ber 2013, t he EudraVigilance dat abase ( bot h post - aut horisat ion & clinical t rials m odules) held a t ot al of 7,026,537 adverse react ion report s, referring t o 4,586,491 individual cases ( see figure 5) . 8,000,000 7,000,000 6,000,000 5,000,000 4,380,679 4,000,000 3,000,000 2,852,329 2,000,000 1,000,000 2,645,858 1,734,162 0 I ndividual cases Adverse react ion report s EEA Non- EEA Figur e 5 . Tot al num ber of individual cases/ adverse react ion report s received in t he EudraVigilance dat abase from it s incept ion in Decem ber 2001 unt il 31 Decem ber 2013. E- r e por t in g st a t us for M AH s a n d sponsor s of clin ica l t r ia ls • A t ot al of 758 MAHs ( at headquart er level) have sent report s t o t he EudraVigilance Post aut horisat ion Module ( EVPM) in t he period bet ween 1 Januar y 2002 and 31 Decem ber 2013. • A t ot al of 713 sponsors of clinical t rials ( at headquart er level) have sent report s t o t he EudraVigilance Clinical Trials Module ( EVCTM) in t he period bet ween 1 May 2004 and 31 Decem ber 2013. Tables 2 and 3 below show t he t ot al ( bot h expedit ed and non- expedit ed) num ber of unique cases and I CSRs t ransm it t ed by MAHs and sponsors t o EVPM and EVCTM and t he 15- day r eport ing com pliance of MAHs and sponsors of clinical t rials when report ing t o EVPM. 15- day report ing com pliance is calculat ed by subt ract ing t he dat e t he I CSR was received by t he EudraVigilance Gat eway ( EV Message Gat eway Dat e) from t he dat e of receipt of t he m ost recent inform at ion ( Receipt Dat e – I CH E2B( R2) A.1.7) . The receipt dat e is t reat ed as day 0, giving t he MAH 15 days following t hat day t o t ransm it t he report s. For t he re- t ransm ission of report s originally t ransm it t ed t o MAHs by ot her organisat ions, t he receipt dat e is t he dat e t he MAH r eceived t he m ost recent inform at ion from t he ot her organisat ion, not t he dat e t hat t he ot her organisat ion received t he m ost recent inform at ion from t he original report er. Nullificat ion and error report s are excluded from t he com pliance calculat ions. Only cases flagged by t he MAHs as serious are included in t he calculat ions. 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 12/ 28 Ta ble 2 . Num ber of I CSRs and unique cases t ransm it t ed by MAHs and sponsors t o EVPM and EVCTM during 2013 EV Module EVPM EVCTM Transm ission t ype Num ber of t ransm issions I CSRs I ndividual Cases I CSRs I ndividual Cases 793,176 502,860 75,341 28,355 Ta ble 3 . Com bined 15- day report ing com pliance t o EVPM for all MAHs and sponsors in 2013. Pe r ce n t a ge of I CSRs t r a n sm it t e d t o EVPM by M AH s/ Spon sor s w it h in 1 5 da ys: 96% E- r e por t in g st a t us for N CAs • All 31 NCAs have been aut horised t o ent er int o product ion wit h EudraVigilance. • All NCAs have report ed I CSRs t o EVPM, except for AFLUV ( Liecht enst ein) and t he Division de la Pharm acie et des Médicam ent s ( Luxem bourg) , for w hom special arrangem ent s are in place: − All I CSRs occurring in Liecht enst ein are t ransm it t ed t o EudraVigilance by MAHs. − The NCA for Luxem bourg has t heir report s t ransm it t ed by t he French nat ional agency. Tables 4 & 5 below shows t he t ot al ( bot h expedit ed and non- expedit ed) num ber of unique cases and I CSRs t ransm it t ed by NCAs t o EVPM and EVCTM and t he 15- day report ing com pliance of NCAs when report ing serious cases t o EVPM. 15- day report ing com pliance is calculat ed by subt ract ing t he dat e t he I CSR was received by t he EudraVigilance Gat eway ( EV Message Gat eway Dat e) from t he dat e of receipt of t he m ost recent inform at ion ( Receipt Dat e – I CH E2B( R2) A.1.7) . The receipt dat e is t reat ed as day 0, giving t he MAH 15 days following t hat day t o t ransm it t he report s. For t he re- t ransm ission of report s originally t ransm it t ed t o NCAs by MAHs, t he r eceipt dat e is t he dat e t he NCA received t he m ost recent inform at ion from t he MAH, not t he dat e t hat t he MAH received t he m ost recent inform at ion from t he original report er. Nullificat ion and error report s are excluded from t he com pliance calculat ions. Only cases flagged by t he NCA as serious are included in t he calculat ions. The overall NCA 15- day report ing com pliance was 89% , an increase from 2011 & 2012, when it was 84% . Ta ble 4 . Num ber of I CSRs and unique cases t ransm it t ed by NCAs t o EVPM & EVCTM during 2013 EV Module EVPM EVCTM Transm ission t ype Num ber of t ransm issions I CSRs I ndividual Cases I CSRs I ndividual Cases 327,925 239,511 19,557 12,161 The figures for “ I ndividual Cases” in t he t able above include t he m ast er cases t ransm it t ed by t he EMA. Ta ble 5 . Com bined 15- day report ing com pliance t o EVPM for all NCAs in 2013 Percent age of I CSRs t ransm it t ed t o EVPM by NCAs wit hin 15 days: 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 89% Page 13/ 28 During 2013, t he following 10 NCAs t ransm it t ed SUSARs t o EVCTM ( SUSARs from ot her count ries were received direct ly from sponsors of clinical t rials) : M e m be r St a t e N a t iona l Com pe t e nt Aut hor it y BELGI UM FEDERAL AGENCY FOR MEDI CI NES AND HEALTH PRODUCTS CZECH REPUBLI C STATE I NSTI TUTE FOR DRUG CONTROL DENMARK DANI SH MEDI CI NES AGENCY FI NLAND FI NNI SH MEDI CI NES AGENCY GERMANY FEDERAL I NSTI TUTE FOR DRUGS AND MEDI CAL DEVI CES GERMANY PAUL- EHRLI CH- I NSTI TUT I TALY AGENZI A I TALI ANA DEL FARMACO NETHERLANDS COLLEGE TER BEOORDELI NG VAN GENEESMI DDELEN SWEDEN MEDI CAL PRODUCTS AGENCY UNI TED KI NGDOM MEDI CI NES & HEALTHCARE PRODUCTS REGULATORY AGENCY Eu dr a Vigila n ce da t a ba se a n d su ppor t of sign a l m a n a ge m e n t pr ocess A t ot al of 19,330 e- RMRs were generat ed in 2013 t o facilit at e t he cont inuous m onit oring of t he safet y of m edicines by t he EMA and m edicines regulat ory aut horit ies in t he EEA. 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 14/ 28 An ne x I I I - Tot a l num be r of m e dicin al pr odu ct su bm ission s by M AH s Tot a l num be r of m e dicina l pr oduct subm ission s by M AH s by 3 Fe b 2 0 1 4 1 7 in a ccor da nce w it h Ar t icle 5 7 ( 2 ) , se con d su bpa r a gr a ph of Re gula t ion ( EC) 7 2 6 / 2 0 0 4 Tot al num ber of m edicinal product s ( count ed on t he basis of 459,290 EudraVigilance codes) Tot al num ber of m arket ing aut horisat ion holders ( legal ent it ies) 3,996 est ablished in t he EU ( corresponding t o EudraVigilance codes) The EudraVigilance code is t he level t o which a product is defined in t he cont ext of t he Art icle 57( 2) . I t encom passes t he following param et ers: • Nam e of t he m edicinal product . • MAH. • Aut horising Com pet ent Aut horit y. • Count ry. • Act ive ingredient ( s) . • St rengt h( s) . • Pharm aceut ical form . • Aut horisat ion num ber. • Aut horisat ion procedure. • Pack size ( only if Com pet ent Aut horit y assigns unique m arket ing aut horisat ion num ber at package level) . 17 Please not e t hat t his figure is as of 3 Feb 2014 and not 31 Dec 2013. This is due t o t echnical changes m ade t o t he dat abase w hich m eans it is not possible t o give a precise figure as of 31 Decem ber 2013. The EMA est im at es t hat t he num ber of MAHs and headquart ers w ould have been alm ost ident ical as of end- 2013 and t he num ber of m edicinal product s w ould have been 10- 20,000 fewer 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 15/ 28 An ne x I V - Eu dra Vigilan ce da t a qu alit y a ct ivit ies I n accordance wit h Regulat ion ( EC) No 726/ 2004, Art icle 24( 3) , t he Agency operat es procedures t o ensure t he qualit y and int egrit y of t he inform at ion collect ed in EudraVigilance. This includes ident ifying duplicat e report s, perform ing t he coding of t he report ed m edicines and report ed act ive subst ances, and providing feedback on t he qualit y of inform at ion sent by NCAs, MAHs and sponsors. The t able below refers t o t he dat a qualit y act ivit ies perform ed by t he EMA in 2013. Eudr a Vigila nce da t a qua lit y a ct ivit ie s in 2 0 1 3 I de nt ifying a nd m a na ging Codin g of r e por t e d m e dicine s Pr oviding fe e dba ck on da t a duplica t e s a nd a ct ive subst a n ce s qua lit y Num ber of duplicat e couples Num ber of m edicinal Tot al num ber of organisat ions assessed: 122,308 ( in 2012 t his product s/ act ive subst ances subj ect t o dat a qualit y review: was 96,298) recoded: 87,660 ( I n 2012 t his 166 ( I n 2012 t his was 216) was 82,076) Num ber of ‘m ast er’ report s Num ber of adverse react ion generat ed based on duplicat ed report s recoded: 555,798 dat a: 65,906 ( I n 2012 t his was ( referring t o 275,852 individual 83,393) cases) . I n 2012 616,001 adverse react ion report s were recoded, referring t o 356,000 individual cases. The overall rat e of duplicat es report ed t o EudraVigilance since it s launch is est im at ed at about 8% . This includes “ different - sender” duplicat es as well as “ sam e- sender” duplicat es. “ Sam e- sender” duplicat es are t hose were all duplicat es in t he clust er were t ransm it t ed t o EudraVigilance by t he sam e organisat ion ( NCAs, MAHs, sponsors) . I n accordance wit h Direct ive 2001/ 83/ EC, Art icles 107( 5) and 107a( 3) , t he Agency is collaborat ing wit h MAHs and NCAs t o det ect and elim inat e duplicat e suspect adverse react ion report s. To t his end, when suspect ed duplicat e suspect adverse react ion report s are det ect ed in EudraVigilance and bot h of t he suspect ed duplicat es are from t he sam e sender, t he Agency will send inform at ion on t hese suspect ed ‘sam e- sender’ duplicat es t o t he organisat ion which t ransm it t ed t hese cases t o EudraVigilance and ask t hem t o m anage t hem appropriat ely. 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 16/ 28 An ne x V – Signa l de t e ct ion I n 2013, t he t ot al num ber of signals reviewed increased by approx. 11% com pared t o 2012. This parallels t he increased num ber of I CSRs received in EudraVigilance, t he increasing use of st andardised MedDRA queries ( SMQs) for analysis ( and subsequent ly a higher num ber of preferred t erm s which are t racked) as well as t he im plem ent at ion of t he list of designat ed m edical event s ( DMEs) in t he e- RMR and addit ional cat egories which warrant priorit y screening ( i.e. m ost relevant react ions t erm s/ DMEs, fat al, paediat ric report s et c.) in 2012. OVERVI EW 2013 2012 2011 2010 2009 2008 Tot al 2,449 2,213 1,586 2,054 1,704 1,327 Difference vs previous year 236 627 - 468 350 377 Ref. Difference % 10.7% 39.5% - 22.8% 20.5% 28.4% Ref. Overall, 91% of pot ent ial signals originat ed from EudraVigilance, wit h ot her sources account ing for: 5% from t he scient ific lit erat ure, 3% from com m unicat ions received from ot her Regulat ory Agencies worldwide ( 52 from MHLW/ PMDA, 15 from t he FDA, 5 from t he WHO and 4 from EMCDDA) and 1% from ot her sources. The overview of signals validat ion by act ion t aken is provided below: N um be r of signa ls % of N um be r of signa ls % of Ja n- D e c 2 0 1 3 t ot a l Ja n- D e c 2 0 1 2 t ot a l Closed 2126 87% 1869 84% Ongoing 211 9% 195 9% Monit ored 69 3% 97 4% Priorit ised and analysed by PRAC 43 2% 52* 2% Tot al 2449 100% 2213 100% Act ion t a k e n * reflect s t he num ber of signals com m unicat ed t o Rapport eurs by t he EMA in 2012 ( prior t o, and aft er t he inaugurat ion of t he PRAC) I n t ot al, 2,449 pot ent ial signals were reviewed in 2013 by t he Agency. 43 signals validat ed and com m unicat ed t o t he Rapport eurs by t he Agency were priorit ised and analysed by t he PRAC during 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 17/ 28 2013. Of not e, 2 of t hese signals had been under m onit oring by t he signal validat ion t eam at t he Agency in 2012, 8 were pr om pt ed by t he scient ific lit erat ure and 5 by inform at ion received from ot her regulat ory aut horit ies ( 3, 5 and 6, respect ively in 2012) . At t he t im e of t his report , approxim at ely half of t he 43 signals handled by t he PRAC ( n= 21) led t o recom m endat ion for changes t o t he product inform at ion, eit her direct ly ( n= 7) or following a cum ulat ive review ( n= 14) , providing inform at ion t o pat ient s and healt hcare professionals on t he safe use of t hese product s. For four signals, t his also included t he dist ribut ion of Direct Healt hcare Professional Com m unicat ions ( DHPC) t o increase awareness about t he new safet y inform at ion. The evaluat ion of 14 signals following t he recom m endat ion for a cum ulat ive review is current ly on- going. The evaluat ion of seven signals was closed wit h no furt her regulat ory act ion required, wit h t he rout ine pharm acovigilance act ivit ies deem ed sat isfact ory for furt her follow- up of t hese signals. One signal led t o a form al evaluat ion of t he benefit - risk balance via an Art icle 31 referral. Addit ionally, 69 signals ( approx. 3% ) were kept under m onit oring ( as of end of Dec 2013) . I f a signal is m onit ored, in principle all new cases of t hat react ion sent t o EudraVigilance ar e reviewed. Ove r vie w of sign a ls va lida t e d by t h e Age n cy pr ior it ise d a n d a ssesse d by t h e PRAC Since t he est ablishm ent of t he PRAC in July 2012, a new signal m anagem ent process has been in place. Signals are com m unicat ed t o PRAC m em bers w ho confirm t he validit y of t he signals in line wit h t he new legislat ion and t he Guideline on good pharm acovigilance pract ices: Module I X – Signal m anagem ent . Confirm ed signals are t ransm it t ed t o t he PRAC for priorit isat ion and analysis. I n line wit h t he new legislat ion’s aim of increasing t ransparency and com m unicat ion in pharm acovigilance, agendas and m inut es of t he PRAC are being m ade public. Since Sept em ber 2013 t his also includes t he recom m endat ions on signals as adopt ed by t he Com m it t ee, and can be found here. An overview of validat ed signals is provided in t he following t ables, including t he lat est regulat ory st at us as of 21 January 2014. When t he out com e of an init ial recom m endat ion is already known, bot h are not ed sequent ially. 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 18/ 28 Drug I ssue Lat est st at us or out com e Adalim um ab Derm at om yosit is cum ulat ive review: updat e of product inform at ion Adalim um ab I m m une Reconst it ut ion I nflam m at ory cum ulat ive review Syndrom e ( I RI S) Aflibercept Blindness cum ulat ive review Agent s act ing on t he renin- Efficacy and safet y of dual blockade Art icle 31 referral: evaluat ion angiot ensin syst em of t he renin- angiot ensin sy st em : ongoing m et a- analysis of random ised t rials Agom elat ine QT prolongat ion cum ulat ive review: no regulat ory act ion ( rout ine pharm acovigilance) Bevacizum ab Anaphylact ic shock cum ulat ive review: no regulat ory act ion ( rout ine pharm acovigilance) Brent uxim ab Vedot in Pulm onary t oxicit y Capecit abine Acut e renal failure cum ulat ive review: updat e of product inform at ion cum ulat ive review: updat e of product inform at ion Capecit abine Convulsion cum ulat ive review Cinacalcet Fat al case wit h severe hypocalcem ia updat e of product inform at ion in a pediat ric clinical st udy and DHPC Clopidogrel Acquired haem ophilia A cum ulat ive review: updat e of Clopidogrel Cross- react ivit y bet ween clopidogrel product inform at ion updat e of product inform at ion and t iclopidine am ong pat ient s wit h previous allergic and/ or haem at ologic react ions t o one of t hese product s Clopidogrel Eosinophilic pneum onia cum ulat ive review: updat e of product inform at ion Denosum ab Vasculit is cum ulat ive review Dexm edet om idine I nfant ile apnoeic at t ack cum ulat ive review Docet axel Serious and fat al drug int eract ions cum ulat ive review: updat e of involving CYP3A4 ( grapefruit j uice product inform at ion and dronedarone) Docet axel Throm bot ic m icroangiopat hy cum ulat ive review: no regulat ory act ion ( rout ine pharm acovigilance) Duloxet ine I nt eract ion wit h aripiprazole - cum ulat ive review: no serot onin syndrom e regulat ory act ion ( rout ine pharm acovigilance) 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 19/ 28 Drug I ssue Lat est st at us or out com e Duloxet ine I nt eract ion wit h linezolid leading t o updat e of product inform at ion serot onin syndrom e Efavirenz; Em t ricit abine, I nt eract ion wit h Ginkgo biloba updat e of product inform at ion Derm at om yosit is cum ulat ive review: updat e of efavirenz, t enofovir Et anercept product inform at ion Exenat ide I nj ect ion sit e abscess and cellult is cum ulat ive review Exenat ide, Liraglut ide Cholecyst it is and cholelit hiasis cum ulat ive review Exenat ide, Liraglut ide Gast roint est inal st enosis and cum ulat ive review: updat e of obst ruct ion product inform at ion Capillary leak syndrom e, cyt okine cum ulat ive review: updat e of release syndrom e product inform at ion and DHPC Heparin- induced t hrom bocyt openia cum ulat ive review: no Filgrast im , Pegfilgrast im Fondaparinux regulat ory act ion ( rout ine pharm acovigilance) Glycopyrronium Angioedem a cum ulat ive review Hum an papillom avirus Com plex regional pain syndrom e cum ulat ive review Com plex regional pain syndrom e cum ulat ive review I m m une Reconst it ut ion I nflam m at ory cum ulat ive review vaccine [ t ypes 16, 18] ( recom binant , adj uvant ed, adsorbed) Hum an papillom avirus vaccine [ t ypes 6, 11, 16, 18] ( recom binant , adsorbed) I nflixim ab Syndrom e ( I RI S) Leflunom ide Drug React ion wit h Eosinophilia and updat e of product inform at ion Syst em ic Sym pt om s ( DRESS) Leflunom ide Myosit is cum ulat ive review: no regulat ory act ion ( rout ine pharm acovigilance) Lenograst im Levet iracet am ( Syst em ic) capillary leak syndrom e cum ulat ive review: updat e of ( CLS) product inform at ion and DHPC Hyponat raem ia and inappropriat e cum ulat ive review: updat e of ant idiuret ic horm one secret ion product inform at ion ( SI ADH) Mirabegron Urinary ret ent ion cum ulat ive review Orlist at Pharm acokinet ic drug int eract ion ( at cum ulat ive review: updat e of absorpt ion) wit h highly act ive product inform at ion ant iret roviral t herapy( HAART) leading t o loss of HAART efficacy 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 20/ 28 Drug I ssue Lat est st at us or out com e Sit aglipt in, Angioedem a due t o int eract ion cum ulat ive review Sit aglipt in/ m et form in bet ween sit aglipt in and ACE inhibit ors Som at ropin Convulsions cum ulat ive review: no regulat ory act ion ( rout ine pharm acovigilance) Tem ozolom ide Hepat ic failure cum ulat ive review: updat e of product inform at ion and DHPC Teriparat ide Anaphylact ic shock updat e of product inform at ion Thalidom ide Post erior Reversible Encephalopat hy cum ulat ive review: updat e of Syndrom e ( PRES) product inform at ion Ticagrelor Food int eract ion wit h grapefruit j uice updat e of product inform at ion Vem urafenib Renal failure cum ulat ive review 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 21/ 28 An ne x VI - Signa l m an a gem en t in t h e EU Signal m anagem ent is t he procedure which covers all t he st eps from t he det ect ion of a new signal t o it s evaluat ion by t he appropriat e scient ific com m it t ee, including t he signal validat ion, signal confirm at ion, signal analysis and priorit izat ion, signal assessm ent , recom m endat ion for act ion and t he exchange of inform at ion bet ween t he relevant part ies. Following t he experience from t he Pilot of signal m anagem ent in t he EU, furt her progress in signal m anagem ent has been m ade t hrough t he Signal Managem ent Review Technical Working Group, a collaborat ion group for cont inuous process im provem ent bet ween t he EMA and t he MSs in t he European Medicines Regulat ory Net work. Three areas were ident ified for facilit at ion of signal m anagem ent in t he EU: Signal m anagem ent t ools and processes, Met hodological guidance and Signal det ect ion m et hods. The following act ions were com plet ed in 2013: • St andardised t em plat es for assessm ent of signal dat a and t he corresponding form for t he PRAC recom m endat ion were developed for t he use by t he net work. • A Quest ions & answers on signal m anagem ent docum ent ( EMA/ 261758/ 2013) was published on t he EMA websit e t o provide procedural guidance for MAHs regarding handling of signals discussed at PRAC and any follow- up act ions t hat m ay arise. • The Agency st art ed publishing t he signal recom m endat ions adopt ed by t he PRAC on a dedicat ed sect ion of t he EMA websit e 18 t o facilit at e im plem ent at ion of t he PRAC recom m endat ions by t he MAHs and t o increase t ransparency. • The European Pharm acovigilance I ssues Tracking Tool dat abase was am ended following t he im plem ent at ion of t he new pharm acovigilance legislat ion, t o accom m odat e t he new st eps in signal m anagem ent process in line wit h t he new legislat ion and t o allow for a m ore com plet e t racking of t he signal life cycle. The user guide was updat ed accordingly. • I nt egrat ion of signal procedures int o t he Agency’s t racking syst em s was achieved, t o allow for t racking of signal procedures and t heir corresponding t im et ables. Furt her work for nat ionally aut horised product s is foreseen in t he fut ure. • Furt her research int o st at ist ical signal det ect ion m et hods was carried out , wit h a view t o updat e t he exist ing Guideline on t he use of st at ist ical signal det ect ion m et hods in EVDAS ( Doc. Ref. EMEA/ 106464/ 2006) . 18 ht t p: / / www .em a.europa.eu/ em a/ index.j sp?curl= pages/ regulat ion/ docum ent _list ing/ docum ent _list ing_000375.j sp&m id= WC0b01ac0580727d1c 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 22/ 28 An ne x VI I - Re qu e st s for infor m a t ion an d docum en t s Sevent y- t wo request s were answered in 2013, com pared t o 80 in 2012. Whereas t he t ot al num ber has rem ained sim ilar, an increase was observed for request s from t he general public, HCPs, t he MAHs and non- EU regulat ory aut horit ies. The drop in request s fr om j ournalist s was observed already in 2012 and cont inued t hroughout 2013. This m ay be due t o t he proact ive publicat ion of adverse drug react ion dat a for CAPs at ww w.adrreport s.eu, which st art ed on 31 May 2012. Dat a from seven request s were used t o support t he decision m aking in t he cont ext of European referral procedures ( list ed below) . The m edian response t im e in 2013 was 23 days ( range 0- 182 days) com pared t o 18 days in 2012 ( range 0- 100 days) . The t im e of response is subj ect t o different fact ors such as t he urgency of t he request , t he com plexit y of t he search needed and t he agreed t im eliness especially for int ernal EU request s. 35% of t he request s were answered wit hin 14 days, 61% wit hin 1 m ont h and 86% wit hin t wo m ont hs which is a decrease com pared wit h 2012 ( 49% , 68% and 95% , respect ively) and reflect s t he increase in com plexit y of request s and num ber of product s/ react ions request ed. An overview is provided below by t ype of request , aut horisat ion t ype of request ed product ( s) , request er t ype, t herapeut ic group of request ed product ( s) and origin count ry ( ext ernal request s only) . 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 23/ 28 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 24/ 28 Ove r vie w of r e que st s h a ndle d in 2 0 1 3 Type of request er Drug/ subst ance I ssue Type of request I nt ernal EU Acet ylsalicylic acid ADRs for acet ylsalicylic acid in Access t o inform at ion Regulat ory Net work low dose and docum ent s MAH Agom elat ine Angioedem a Access t o docum ent s Law firm Alendronat e Alendronat e - ONJ Access t o inform at ion Flut am ide Flut am ide - Deat h Om eprazole Om eprazole - Hepat it is and Rim onabant Hepat ot oxicit y Rim onabant - Depression, m anic depression and m ent al disorders I nt ernal EU Aliskiren Regulat ory Net work Dat a of use in paediat ric Access t o inform at ion populat ion and docum ent s PML Access t o inform at ion I CSRs subm it t ed wit hin t he Access t o inform at ion I nt ernal EU All subst ances in t he Regulat ory Net work dat abase General Public Allopurinol Non- EU Regulat ory Andrographis All I CSR subm it t ed t o t he Aut horit ies paniculat a ( Burm .f.) dat abase Skin SOC Access t o inform at ion Nees. I nt ernal EU Ant idiabet ic Pancreat it is and pancreat ic Regulat ory Net work m edicines cancer Non- EU Regulat ory Arcoxia - et oricoxib - Fat al out com es Access t o inform at ion - Cardiac disorders and docum ent s Aut horit ies Access t o inform at ion - Cent ral nervous syst em - Vascular disorders Academ ia I nt ernal EU Ast hm a m edicat ions All ADRs report ed in children Access t o docum ent s in children subm it t ed from 2007 t o 2011 At osiban Cont am inat ion issues Access t o inform at ion Avast in - Anaphylact ic shock Access t o docum ent s Ocular use Access t o inform at ion Regulat ory Net work MAH bevacizum ab I nt ernal EU Avast in - Regulat ory Net work Bevacizum ab I nt ernal EU Azit hrom ycin Fat al arrhyt hm ias Access t o docum ent s Bedaquiline All ADRs report ed t o t he Access t o inform at ion Regulat ory Net work Journalist dat abase I nt ernal EU Benzyl Alcohol Gasping syndrom e Access t o inform at ion I nt ernal EU Biphasic insulin Hom ogeneit y issue Access t o inform at ion Regulat ory Net work aspart Journalist Cabazit axel Medicat ion errors Access t o inform at ion Non- EU Regulat ory Clopidogrel Acquired haem ophilia A Access t o docum ent s Regulat ory Net work Aut horit ies 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 25/ 28 Type of request er Drug/ subst ance I ssue Type of request I nt ernal EU Codeine Dat a t o support t he Referral Access t o inform at ion Regulat ory Net work General Public procedure Colchicine and All I CSRs subm it t ed t o t he Access t o inform at ion m et hot rexat e dat abase I nt ernal EU Com bined oral Dat a t o support t he Referral Regulat ory Net work cont racept ives procedure I nt ernal EU Cont racept ives Em bolic and t hrom bot ic event s Access t o docum ent s Cyprot erone Dat a t o support t he Referral Access t o inform at ion Access t o inform at ion Regulat ory Net work I nt ernal EU Regulat ory Net work I nt ernal EU procedure Dext rom et horphan ADRs report ed in t he EU Access t o inform at ion Academ ia Diabet ic m edicines Research Prot ocol Access t o inform at ion I nt ernal EU Diacerein Dat a t o support t he Referral Access t o inform at ion Regulat ory Net work Regulat ory Net work MAH procedure Digoxin Det ails of all t he I CSRs Access t o docum ent s Am it ript yline subm it t ed Academ ia Dom peridone All I CSRs subm it t ed t o t he Access t o inform at ion dat abase and docum ent s I nt ernal EU Dom peridone Dat a t o support t he Referral Access t o inform at ion Regulat ory Net work Journalist I nt ernal EU procedure Drospirenone Efavirenz Regulat ory Net work All ADRs report ed t o t he Access t o inform at ion dat abase and docum ent s Cancer report s and birt h Access t o inform at ion defect s General Public Enoxaparin Cardiovascular disorders Access t o inform at ion Journalist Exenat ide Cancer of t he t hyroid and Access t o inform at ion Liraglut ide pancreat ic glands Lixisenat ide Sit aglipt in Saxaglipt in Linaglipt in Vildaglipt in I nt ernal EU Fluenz and Fluariz Medicat ion errors Access t o inform at ion Flupirt ine Dat a t o support t he Referral Access t o inform at ion Regulat ory Net work I nt ernal EU Regulat ory Net work European procedure Gardasil Mult iple Sclerosis Parliam ent I nt ernal EU Access t o inform at ion and docum ent s Gilenya - fingolim oid PML Access t o inform at ion Gilenya - fingolim oid PML Access t o inform at ion Havrix, Engerix and Mult iple sclerosis Regulat ory Net work I nt ernal EU Regulat ory Net work General Public and docum ent s Access t o docum ent s Twinrix 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 26/ 28 Type of request er Drug/ subst ance I ssue Type of request I nt ernal EU Heparins Trend analysis of ADRs Access t o inform at ion Hexoprenaline All I CSRs subm it t ed t o t he Access t o inform at ion dat abase and docum ent s Com plex regional pain Access t o inform at ion Regulat ory Net work I nt ernal EU Regulat ory Net work Non- EU Regulat ory HPV Vaccines Aut horit ies MAH syndrom e Hydroxyet hyl st arch Tot al of I CSRs and cases Access t o inform at ion report s wit h fat al out com e I nt ernal EU I not uzum ab Veno- occlusive disease and Access t o inform at ion Regulat ory Net work ozogam icin hepat ot oxicit y and docum ent s I nt ernal EU I nt erferon bet a Risk of collapsing focal Access t o inform at ion Regulat ory Net work Non- EU Regulat ory segm ent al glom erulosclerosis I nt ralipid Report s of ADRs subm it t ed for Access t o inform at ion an specific form ulat ion and docum ent s Lopinavir/ rit onavir Drug int eract ion bet ween Access t o docum ent s and quet iapine prot ease inhibit ors and Aut horit ies MAH quet iapine HCP Magnesium sulfat e, All ADRs report ed t o t he Access t o inform at ion t hiam ine and dat abase and docum ent s procaine MAH Mirt azapine Pancreat it is Access t o docum ent s Ot her EU Agencies MMR Vaccines I nform at ion on ADRs of MMR Access t o inform at ion vaccines in adult s. Academ ia Mult iple subst ances Research prot ocol Access t o inform at ion General Public Nat alizum ab PML Access t o docum ent s I nt ernal EU Nicot inic acid Dat a t o support t he Referral Access t o inform at ion Regulat ory Net work I nt ernal EU procedure Num et a G13% E Regulat ory Net work HCP Hyperm agnesaem ia in pret erm Access t o inform at ion infant s Paracet am ol Allergic react ions Access t o inform at ion and docum ent s Ot her EU Agencies Phenibut All I CSRs subm it t ed t o t he Access t o inform at ion dat abase I nt ernal EU Privigen Haem olysis Access t o inform at ion Ranbaxy product s Qualit y issues Access t o inform at ion Resorcinol Endocrine, skin and Access t o inform at ion subcut aneous disorders and docum ent s Growt h ret ardat ion in children Access t o docum ent s Regulat ory Net work I nt ernal EU Regulat ory Net work Consult ancy MAH Sert raline and adolescent s HCP Sodium picosulphat e Convulsions, seizures and Access t o inform at ion + m agnesium cit rat e epilepsy and docum ent s Polyet hylene glycol 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 27/ 28 Type of request er Drug/ subst ance I ssue Type of request At ypical fem ur fract ure Access t o inform at ion ( m acrogol) + ascorbic acid/ ascorbat e Oral polyet hylene glycol ( m acrogol) MAH St ront ium ranelat e and docum ent s I nt ernal EU Synflorix Regulat ory Net work Non- EU Regulat ory I nform at ion on case report s Access t o inform at ion from clinical t rials Tacrolim us Medicat ion errors Access t o inform at ion Thiocolchicoside Genot oxicit y Access t o inform at ion I nt ernal EU Tolcapone, Tolcapone - Hepat ic disorders Regulat ory Net work nat alizum ab and Nat alizum ab - PML aloset ron Aloset ron - Gast roint est inal Aut horit ies I nt ernal EU Regulat ory Net work and docum ent s Access t o inform at ion disorders I nt ernal EU Tredapt ive Regulat ory Net work ( laropiprant , nicot inic All ADRs report ed Access t o inform at ion acid) Ot her EU Agencies Tropicam ide Misuse and abuse Access t o inform at ion HCP Valproat e Middle or/ and inner ear Access t o inform at ion Non- EU Regulat ory Xaluprine - Aut horit ies m ercapt opurine MAH Yellox - brom fenac m alform at ion Medicat ion errors Access t o I nform at ion Cardiac failure Access t o docum ent s 2013 Annual Report on EudraVigilance for t he European Par liam ent , t he Council and t he Com m ission EMA/ 145085/ 2014 Page 28/ 28